Digital Anatomics raises €420K Series A from Sabadell BStartup for AI-powered spinal surgery

What's the deal? BStartup Banco SabadellDealroom has a profile for this one. Try Dealroom → has invested in Digital AnatomicsDealroom has a profile for this one. Try Dealroom →, a Spanish medtech startup using AI to transform spinal surgery. The €420,000 round was led by BStartup alongside Coben and other private investors.

Digital Anatomics has built XPINE, a cloud-native platform that combines AI, automated radiological analysis, and 3D design to generate personalised surgical guides in 48–72 hours — down from the 15–30 days typical in the sector. The company reports a 16% improvement in screw placement accuracy, 75% less radiation exposure, and 37 fewer minutes per surgery.

It has already been used in more than 500 surgeries across over 65 hospitals internationally.

Why now? Up to 40% of pedicle screws can be poorly positioned using traditional techniques, and roughly 20% of patients require reoperation. Ageing populations and mounting pressure on healthcare systems are driving demand for solutions that improve outcomes without adding cost or complexity.

Existing robotic and navigation systems carry high capital costs. Digital Anatomics' software-first approach offers global scalability at a fraction of the price, with gross margins of 80–90% on a per-procedure recurring model.

What could go wrong? Medtech startups face lengthy regulatory pathways and slow hospital procurement cycles. Convincing surgeons to adopt new tools — especially AI-driven ones — requires robust clinical evidence and trust-building that takes time. Competing against well-funded robotics incumbents with established hospital relationships is another challenge.

At €420,000, the round is modest. Digital Anatomics will likely need significantly more capital to scale internationally and secure additional regulatory approvals.

The signal: Digital Anatomics' traction — more than 500 surgeries across 65-plus hospitals — is notable for a company at the early growth stage raising a relatively modest round, suggesting strong product-market fit before heavy capitalisation. With per-procedure recurring revenue and 80–90% gross margins, the model mirrors the kind of scalable software economics that attract larger follow-on investors in medtech, positioning the startup for a significantly bigger raise as it pushes into new markets.

Read more: capital-riesgo.es